Fig. 5
Dynamic m6A modification of NOG orchestrates the differentiation stage. A The relative gene expression and mRNA expression of NOG during DPSC differentiation. B The protein expression level of NOG detected by western blotting. C Visual data of high-confidence m6A peaks enriched in NOG mRNA detected by m6A RIP-seq. D Details of vectors containing fragments of the NOG 3′ UTR with the wild-type m6A motif or two independent m6A mutants (A-to-T mutation). The numbers (450, 463 and 571, 583) represent the positions of the m6A sites relative to the 3′ UTR. E qPCR assay of the mRNA expression of NOG in 293T cells transduced with the wild-type or m6A-mutant vector (n = 3). F m6A RIP-qPCR demonstrated the m6A deposition alteration in NOG mRNA after METTL3 inhibition. G Immunofluorescence staining showed the METTL3 and NOG expression in the composites of β-TCP/HA scaffolds with METTL3-knockdown DPSCs after subcutaneous transplantation in nude mice for 4 weeks. H Subcutaneous transplantation of DPSCs transduced with METTL3 overexpression and control lentivirus. I The expression level of METTL3 and NOG evaluated by imageJ. Significance was determined via ANOVA or Student’s t test; the data are presented as the mean ± SD (n ≥ 3). *p < 0.05. **p < 0.01. ***p < 0.001